Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
PacBio (NASDAQ: PACB) has announced its upcoming second quarter 2024 financial results conference call, scheduled for Wednesday, August 7, 2024, at 4:30 pm Eastern Time (1:30 pm Pacific Time). Investors and interested parties can access the webcast through PacBio's investor relations website. For those preferring a dial-in option, toll-free and international numbers are provided. Participants are advised to join the call ten minutes before the start time. This event will provide insights into PacBio's financial performance and potentially discuss key developments in the genomics and life sciences sector.
PacBio (NASDAQ: PACB) and the international Consortium for Long-Read Sequencing (CoLoRS) have launched the first publicly available HiFi long-read variant frequency database. This database, globally representative and free, addresses critical gaps in rare disease research by providing access to genetic variants undetectable through short-read sequencing.
Notably, long-read sequencing detects 15,000 more structural variants and 300,000 more small variants than short-read methods. The CoLoRS database, incorporating data from nearly 1,000 long-read genomes, aids in understanding complex genetic variations and their disease implications. This initiative supports significant advancements in oncology, rare diseases, and genetic disorders research.
Ambry Genetics and PacBio (PACB) have announced a collaboration with the University of California, Irvine (UCI) and the GREGoR Consortium to support the Pediatric Mendelian Genomics Research Center program. This initiative aims to sequence up to 7,000 human genomes over three years, focusing on rare diseases. The research will leverage long-read sequencing technology to uncover new genetic variants and enhance understanding of disease biology. The collaborative effort is expected to provide insights that could revolutionize diagnostic capabilities for rare diseases.
PacBio announced its financial results for the first quarter of 2024, reporting a revenue of $38.8 million, a 16% increase in gross profit compared to the prior year, and a net loss of $78.2 million. The company highlighted new product launches and cost-cutting measures to improve revenue and reduce expenses. Cash, cash equivalents, and investments totaled $561.9 million at the end of March 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.